OtherFormulationMixed resultsPreclinical onlyTier 1 · lab
Journal of thermal biology · Feb 2026
This computational study developed an intelligent framework (unsupervised neural networks optimized by a hybrid GA-SQP scheme) to model radiative magneto-thermal behavior of a tri-hybrid nanofluid (copper oxide, titanium oxide, silicon oxide) suspended in human blood modeled as a Casson fluid. The model found a 14% decline in the thermal profile with higher Prandtl number and a 15% increase in temperature with increased radiation parameter; results were validated against an Adams numerical method and assessed with error and convergence analyses.
Reported effects: change in thermal profile with higher Prandtl number 14% · change in temperature with uplift in radiation parameter 15%
Key findings
- Developed a radiative magneto-thermal model of a tri-hybrid nanofluid (CuO, TiO2, SiO2) in human blood modeled as Casson fluid using an intelligent ANN framework optimized by GA-SQP.
- Observed a 14% decline in the thermal profile for higher values of the Prandtl number.
- Observed a 15% growth in temperature with an uplift in the radiation parameter.
- Results were compared to a reference solution obtained via the Adams numerical method and validated via numerical comparisons, statistical error estimation, and convergence analysis.
Limitations: Computational modeling study only; no in vitro, animal, or human experimental data presented.; Blood properties modeled (Casson fluid) rather than measured from biological samples.; Findings are parameter-dependent model outputs and may rely on assumptions not validated experimentally.; No reported biological or clinical validation of heating effects in tissue or tumors..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationReported positiveLimited evidenceTier 4 · clinical
Small methods · Jul 2025 · review
non-small cell lung cancer
This is a review article summarizing how nanomedicines are being developed to support immunotherapy for non-small cell lung cancer. The authors survey core features and the current clinical status of strategies such as immune checkpoint blockade, antibody-drug conjugates, cell engagers, adoptive cells, and cancer vaccines, and emphasize recent nanomedicine developments that may boost these approaches. The abstract highlights advantages of nanomedicines including tumor targeting, improved bioavailability, reduced systemic toxicity, and potential to overcome immune resistance. No new experimental data or quantitative results are reported in the abstract.
Studied with: immune checkpoint blockade, antibody-drug conjugates, cell engagers, adoptive cells, cancer vaccines.
Key findings
- Nanomedicines may offer advantages including specific targeting of tumor cells, improved drug bioavailability, reduced systemic toxicity, and overcoming of immune resistance.
- The review surveys the core features and current clinical status of NSCLC immunotherapy strategies: immune checkpoint blockade, antibody-drug conjugates, cell engagers, adoptive cells, and cancer vaccines.
- Particular emphasis is placed on recent developments of nanomedicines that boost these immunotherapy strategies.
Limitations: This is a review article; no new experimental or clinical trial data are presented in the abstract.; Abstract provides no quantitative results, sample sizes, doses, or outcome metrics.; Species, specific clinical trial identifiers, and funding sources are not specified in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationReported positiveLimited evidenceTier 4 · clinical
European journal of medical research · Jun 2025
tumors (general)brain tumors (drug delivery across the blood-brain barrier)
This review summarizes recent developments in magnetic (superparamagnetic) nanoparticles for biomedical use. It describes their physicochemical properties, surface functionalization, and applications including MRI contrast enhancement, targeted drug delivery (including across the blood-brain barrier), and hyperthermia-based cancer therapies that produce localized heat to kill malignant cells.
Key findings
- Magnetic nanoparticles (MNPs) have high surface-area-to-volume ratio, adjustable size, magnetic sensitivity, and biological compatibility.
- External magnetic fields enable precise control of MNPs for targeted therapeutic and diagnostic applications.
- MNPs have been explored for MRI enhancement, selective drug transport, hyperthermia cancer therapy, and biomolecular separation.
- In oncology MNPs can facilitate direct delivery of therapeutic compounds to tumors, potentially reducing systemic side effects and increasing treatment specificity.
- MNPs can produce localized heat under alternating magnetic fields, which is useful for hyperthermia therapy to selectively eradicate malignant cells.
- Surface functionalization with polymers, ligands, and stabilizers improves stability, minimizes immune responses, and optimizes in vivo performance.
Limitations: Review article with no original experimental data reported in this paper.; Abstract provides no quantitative results, clinical trial data, species, dosing, or sample-size information.; Potential translational gaps between preclinical/technical studies and clinical implementation are not addressed in detail in the abstract.; Broad summary without methodological details or critical appraisal provided in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Lab · in vitroFormulationReported positivePreclinical onlyTier 1 · lab
Nanoscale · Jul 2024
The authors developed zwitterionic thermoresponsive nanoparticles with an upper critical solution temperature (UCST) tuned to 43 °C to deliver paclitaxel intracellularly and release it upon hyperthermia. In cell experiments, the nanoparticles released nearly all encapsulated drug after 1 hour at 43 °C while retaining more than 95% of the payload at 37 °C, and paclitaxel-loaded nanoparticles produced greater therapeutic effects on ovarian cancer cells than non-encapsulated paclitaxel.
Reported effects: payload release after 1 h at 43 °C · payload retained at 37 °C
Studied with: paclitaxel.
Key findings
- Thermoresponsive nanoparticles (NPs) with UCST behavior were synthesized via RAFT emulsion polymerization combining polyzwitterionic stabilizers and an oligoester biodegradable core.
- The cloud point (Tcp) of the NPs was tuned to match hyperthermia treatment needs at 43 °C and used to control paclitaxel delivery.
- "The NPs released almost entirely the encapsulated drug only following 1 h incubation at 43 °C, whereas they retained more than 95% of the payload in the physiological environment (37 °C), thus demonstrating their efficacy as on-demand drug delivery systems."
- Administration of drug-loaded NPs to ovarian cancer cells produced therapeutic effects that outperformed conventional administration of non-encapsulated paclitaxel.
Limitations: In vitro cell-based study only; no in vivo or human data reported in the abstract.; Abstract does not report quantitative cytotoxicity metrics, cell line identities, sample sizes, or statistical analysis details.; No pharmacokinetic, biodistribution, safety, or long-term efficacy data presented..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewFormulationMixed resultsPreclinical onlyTier 4 · clinical
Journal of controlled release : official journal of the Controlled Release Society · Sep 2023
deep tumors
This is a review of sonodynamic therapy (SDT), which combines low-intensity ultrasound with sonosensitizers to produce reactive oxygen species (ROS). The authors summarize mechanisms of SDT, discuss limitations of current organic and inorganic sonosensitizers, and describe stimuli-responsive nano-sonosensitizers as an approach to improve specificity and safety for treating tumors and bacterial infections, while highlighting barriers to clinical translation.
Studied with: low-intensity ultrasound.
Key findings
- SDT produces lethal reactive oxygen species (ROS) via the combination of low-intensity ultrasound and sonosensitizers; ROS-mediated damage is the main mechanism.
- Traditional organic small-molecule sonosensitizers have poor water solubility, strong phototoxicity, and insufficient targeting ability.
- Inorganic sonosensitizers often have low ROS yield and poor biocompatibility.
- Designing stimuli-responsive nano-sonosensitizers that exploit local lesion microenvironment characteristics and ultrasound stimulation may enable more efficient, specific, and safer therapy.
- The review covers accepted SDT mechanisms, classification of response patterns, applications in tumor and bacterial infection treatment, and discusses potential limitations and future perspectives needed for clinical translation.
Limitations: This article is a review and does not present new experimental or clinical trial data.; Discussion is primarily about preclinical and conceptual advances; clinical translation remains unproven and is noted as hindered.; No specific human trial outcomes or quantitative clinical efficacy data are reported in the abstract..
Reviews sonodynamic therapy and stimuli-responsive nano-sonosensitizers specifically for application against deep tumors (and MDR bacterial infections).
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationReported positiveLimited evidenceTier 4 · clinical
Pharmaceutics · Jun 2023
This editorial/review addresses drug delivery in photodynamic therapy (PDT). The abstract fragment states PDT is a non-invasive and selective option for solid tumors and non-oncological diseases but gives no specific experimental results, compounds, or quantitative data.
Key findings
- Photodynamic therapy (PDT) is described as a non-invasive and selective treatment option for solid tumors and non-oncological diseases.
- The article's topic is drug delivery in the context of PDT.
Limitations: Article is an editorial/review and does not present primary experimental data.; Provided abstract is truncated and contains minimal information.; No study design, methods, sample size, species, doses, or quantitative results are reported in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Lab · in vitroFormulationReported positivePreclinical onlyTier 1 · lab
RSC advances · Mar 2023
The authors designed and fabricated a magnetized nanobiocomposite composed of chitosan hydrogel, silk fibroin, PVA and Fe3O4 magnetic nanoparticles for biological applications and specifically evaluated its potential for hyperthermia cancer therapy. They characterized the material (FT-IR, XRD, EDX, FE-SEM, TGA, VSM), found it hemocompatible and non-toxic to healthy cells by MTT and hemolysis testing, and reported it caused cancer cell death of 20.23% in vitro. The authors concluded it shows potential as a candidate for hyperthermia cancer therapy.
Reported effect: cancer cell death 20.23%
Key findings
- A multifunctional nanobiocomposite combining chitosan hydrogel, silk fibroin, PVA and Fe3O4 magnetic nanoparticles was fabricated for biological and hyperthermia cancer therapy applications.
- Structural analyses were performed by FT-IR, XRD, EDX, FE-SEM, TGA and VSM.
- MTT and hemolysis testing indicated the material is hemocompatible and non-toxic for healthy cells.
- The nanobiocomposite caused death of cancer cells to some extent (20.23%).
- The authors evaluated the material's ability for hyperthermia cancer therapy and suggested it can be introduced as an excellent candidate for such applications.
Limitations: In vitro only (MTT and hemolysis); no animal or human data reported.; Abstract does not specify which cancer cell lines were tested or sample sizes.; Only a single quantitative efficacy value reported (20.23% cancer cell death); no statistical measures (p-values, CIs) or controls detailed.; No dosing, exposure time, or experimental conditions provided for the cytotoxicity or hyperthermia experiments.; Claims of suitability as an "excellent candidate" are not supported by in vivo efficacy or safety data in this abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
OtherFormulationReported positivePreclinical onlyTier 1 · lab
Computer methods and programs in biomedicine · Nov 2022
unspecified neoplasm
The authors developed a virtual three-dimensional model (a cat's back) and used computer simulations to test three scenarios of magnetic nanoparticle-mediated hyperthermia. The simulations evaluated the impact of magnetic nanoparticles in different configurations and reported that the method can help minimize heating of healthy tissue and assist personalized planning of dose and nanoparticle distribution for hyperthermia.
Key findings
- Developed a 3D virtual model of a cat's back to simulate magnetic nanoparticle hyperthermia.
- Tested three different simulation scenarios to show the impact of magnetic nanoparticles in different environment configurations.
- Simulation results reported that the method can minimize affection (damage) to healthy tissue.
- Authors conclude the virtual method can help personalize therapy planning and tailor dose and distribution of magnetic nanoparticles for enhanced hyperthermia.
Limitations: In silico simulation only; no in vivo or clinical validation reported in the abstract.; Model used a cat's back anatomy, which may limit generalizability to human patients.; Abstract provides no quantitative results or metrics of heating, efficacy, or safety.; No information on sample size, validation against experiments, or prospective testing..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationReported positivePreclinical onlyTier 1 · lab
Advanced drug delivery reviews · Oct 2022
cancer (general)
This is a narrative review of sonodynamic therapy (SDT) for cancer and how nanomedicine can shape sonosensitizers and US-responsive agents. The authors summarize mechanisms proposed for SDT, emphasize the importance of sonosensitizer physicochemical properties and localization, and argue that nanosystems can both deliver and act as therapeutic agents to enhance sonodynamic anticancer effects.
Studied with: nanomedicine, ultrasound.
Key findings
- SDT uses sonosensitizers activated by non-thermal ultrasound that can penetrate deeply into tissues.
- The mechanisms by which ultrasound triggers sonosensitizer activity are not yet clearly elucidated, which slows clinical application.
- Physicochemical properties of sonosensitizers and their cellular localization are important determinants of their bioeffects.
- Nanomedicine enables shaping of ultrasound-responsive agents to enhance specific sonodynamic effects, including sonoluminescence-mediated anticancer effects.
- There has been substantial recent improvement in SDT driven by advances in nanosized materials, and a shift from delivery systems to nanosystems acting as therapeutic agents is highlighted as important for SDT development.
Limitations: This article is a review and does not present new primary experimental or clinical data.; Mechanisms of sonodynamic therapy remain incompletely understood according to the authors.; Clinical application is noted as limited/slow due to mechanistic uncertainty; translation from preclinical work to humans is not established in this review..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
OtherFormulationReported positivePreclinical onlyTier 1 · lab
Scientific reports · Aug 2022
The authors propose a Janus-Nanojet design based on toroidal plasmonic nanoparticles intended to produce asymmetric (directional) photothermal heating. Using thermoplasmonic numerical calculations they report superior photothermal conversion (noting a temperature figure as "[Formula: see text] K") and claim the design can channel over 90% of generated thermal energy onto a target. They discuss potential relevance for hyperthermia cancer therapies and note this motivates fabrication efforts.
Reported effect: percent_energy_channelled 90%
Key findings
- Proposed a Janus-Nanojet heating unit based on toroidal plasmonic nanoparticles that is intended to generate and release local heat directionally under unpolarized illumination.
- Thermoplasmonic numerical calculations indicate superior photothermal conversion features (up to [Formula: see text] K).
- Numerical results suggest the nanoheaters are able to channel up over 90% of the total thermal energy onto a target.
- Authors discuss relevance of these nanoheaters for thermoplasmonics and hyperthermia cancer therapies and motivate development of fabrication techniques.
Limitations: Study is entirely based on numerical/thermoplasmonic modeling; no in vitro, animal, or human experiments reported.; The abstract does not report an explicit numeric temperature value (uses placeholder '[Formula: see text] K').; Practical fabrication, biological delivery, safety, and efficacy in biological systems were not tested in this study..
Computational design study of a nanoparticle intended for photothermal hyperthermia applications in cancer, but without experimental biological validation.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewFormulationReported positivePreclinical onlyTier 1 · lab
Bioconjugate chemistry · Jun 2022
cancer (various types, not specified)
This review summarizes recent developments in molecular imaging-guided sonodynamic therapy (SDT), focusing on nanoparticle-based sonosensitizers. It discusses SDT mechanisms (cavitation, sonoluminescence, reactive oxygen species, mechanical damage), major molecular imaging techniques and nanoparticle design principles, and summarizes imaging-guided SDT applications for cancer, bacterial infections, and vascular diseases.
Key findings
- Low-intensity ultrasound-triggered sonodynamic therapy (SDT) is a noninvasive modality with strong tissue penetration.
- Nanoparticle-based sonosensitizer-mediated SDT has been widely investigated with developments in nanotechnology.
- Sonosensitizers with imaging capabilities have been developed to determine optimal therapeutic windows and enhance treatment efficacy.
- Prevalent SDT mechanisms include ultrasonic cavitation, sonoluminescence, reactive oxygen species, and mechanical damage.
- The review introduces major molecular imaging techniques and nanoparticle design principles to achieve efficient imaging.
- Imaging-guided SDT applications summarized include treatment of cancer, bacterial infections, and vascular diseases, with the goal of aiding clinical translation.
Limitations: Review article — presents synthesis of existing studies rather than new experimental data.; Focus is on nanoparticle development and imaging-guided approaches (largely preclinical); the abstract does not report clinical trial evidence.; Heterogeneity of modalities and targets discussed may limit ability to draw firm, generalizable conclusions..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationReported positivePreclinical onlyTier 1 · lab
Military Medical Research · Jun 2022 · systematic review
glioblastoma multiformebrain tumors
This review summarizes recent studies of nanosensitizers used in sonodynamic therapy (SDT) for glioblastoma. It explains that SDT combines sonosensitizers with low-intensity ultrasound to kill deep-seated tumors but that conventional sensitizers have limited ability to reach brain tumors across the blood-brain barrier. The authors highlight that multifunctional nanosensitizers and new combination strategies have improved SDT selectivity and tumor-killing ability while reducing side effects, and they outline promising directions for future research.
Studied with: low-intensity ultrasound.
Key findings
- Glioblastoma multiforme (GBM) is highly invasive, genetically heterogeneous, and protected by the blood-brain barrier, all of which reduce treatment efficacy.
- Sonodynamic therapy (SDT) uses activated sonosensitizers coupled with low-intensity ultrasound and can provide tumor-killing effects for deep-seated tumors such as brain tumors.
- Conventional sonosensitizers cannot effectively reach the tumor region in the brain and kill additional tumor cells, indicating a need for delivery strategies across the blood-brain barrier.
- Development of multifunctional nanosensitizers and emerging combination strategies has improved the killing ability and selectivity of SDT and is associated with fewer side effects.
- The review systematically summarizes previous studies on SDT for GBM and highlights recent developments and promising future directions.
Limitations: This is a review article and does not present new experimental or clinical trial data.; The abstract implies focus on technological and preclinical advances; clinical evidence for nanosensitizer SDT in GBM is not reported in the abstract.; Because the article summarizes prior studies, conclusions depend on the design and quality of the included studies (which may be preclinical/in vitro or animal models)..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewAbsorption (PK)Reported positiveModerate evidenceTier 4 · clinical
European journal of nuclear medicine and molecular imaging · May 2022
metastatic neuroendocrine tumoursprostate adenocarcinoma
This EANM Dosimetry Committee paper reviews reported dosimetry data for therapies using lutetium-177-labelled somatostatin-receptor and PSMA-targeting ligands. It summarizes radiation-induced side effects and dose–effect relationships for normal tissues and tumours, and provides practical guidance to encourage patient-specific dosimetry in centres offering these therapies.
Key findings
- Provides an overview of reported dosimetry data for 177Lu-labelled somatostatin-receptor and PSMA-targeting therapies.
- Summarises current knowledge about radiation-induced side effects on normal tissues and dose–effect relationships for tumours.
- Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and skin in case of radiopharmaceutical extravasation.
- Where applicable, guidance is provided taking into account the present status of the field and recent evidence.
- The recommendations aim to encourage the practice of patient-specific dosimetry and propose methods suitable for centres offering 177Lu-labelled ligand therapy.
Limitations: This is an overview/recommendation document rather than a report of new primary clinical trial data.; The abstract does not present original quantitative patient-level results, sample sizes, or statistical outcomes.; Recommendations are framed on the present status of the field and recent literature, which may limit generalisability as evidence evolves..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Lab · in vitroFormulationReported positivePreclinical onlyTier 1 · lab
Nanoscale · Apr 2022
Researchers loaded the probiotic bacterium Lactobacillus fermentum with gold and magnetic nanoparticles using two different synthetic strategies, including a novel layer-by-layer EPS approach. They characterized the resulting bacteria–nanoparticle constructs by SEM, TEM and UV–vis and showed the constructs produced heat when exposed to an alternating magnetic field or near-infrared laser light. The authors suggest these heterobimetallic systems could be developed as oral magnetothermal/photothermal agents for gastric diseases including cancer, but no animal or human testing was reported.
Studied with: gold nanoparticles, magnetic nanoparticles.
Key findings
- Two synthetic strategies produced heterobimetallic systems: (1) simultaneous loading of AuNP and MNP into the same EPS layer (AuNP + MNP-bacteria) and (2) sequential loading to form distinct EPS layers (AuNP-bacteria-EPS-MNP).
- The second, layer-by-layer strategy exploits EPS–EPS recognition and is reported as not previously described.
- Samples were characterized by scanning and transmission electron microscopy and UV–vis spectroscopy.
- Both heterobimetallic AuNP/MNP-bacteria systems generated heat under exposure to an alternating magnetic field (magnetic hyperthermia) and under near-infrared laser light (photothermal therapy).
Limitations: Materials/physical study only (no cell culture, animal, or human efficacy data reported).; No safety, toxicity, biodistribution, or oral-delivery performance data reported in this abstract.; No quantitative heating metrics or sample sizes are reported in the abstract.; Potential clinical application (oral cancer agents) is speculative and was not tested in vivo or clinically..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Lab · in vitroFormulationReported positivePreclinical onlyTier 1 · lab
ACS applied materials & interfaces · May 2021
osteosarcoma (canine OSCA-8 cell line)
This study developed a method to selectively detect magnetic nanowires (MNWs) among multiple magnetic signals and characterized MNWs and magnetic biopolymers. MNWs were surface-functionalized and internalized into canine osteosarcoma (OSCA-8) cells for labeling, manipulation, and separation, and tuning MNW coercivity produced distinct magnetic labels that could be demultiplexed from biopolymer signals.
Key findings
- Introduced a projection method to selectively detect and demultiplex the magnetic signatures of MNWs inside cells from those inside magnetic biopolymers.
- Surface-functionalized MNWs were internalized into canine osteosarcoma (OSCA-8) cancer cells for cell labeling, manipulation, and separation.
- Tuning the coercivity and thereby the irreversible switching field of MNWs was effective for generating distinct magnetic biolabels for selective detection of cancer cells.
- Prepared and characterized magnetic biopolymers as multimodal platforms to distinguish biopolymer magnetic signatures from those of labeled cells.
Limitations: In vitro study using a cell line (canine OSCA-8); no in vivo or clinical data reported in the abstract.; No quantitative results, sample sizes, or statistical analyses are reported in the abstract.; No assessment of therapeutic efficacy (e.g., drug delivery outcomes, hyperthermia effects, or impact on cell proliferation/survival) is provided.; Abstract does not report safety, toxicity, or biodistribution data..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationReported positivePreclinical onlyTier 1 · lab
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Mar 2021
cancertumors
This is a review of sonodynamic therapy (SDT), a noninvasive approach that combines low-intensity ultrasound with sonosensitizers to target cancer. The authors discuss key SDT equipment technologies (ultrasonic dosing, sensitizer screening, tumor positioning, temperature monitoring, and ROS detection) and summarize sonosensitizer development from small molecules to various nano/micro-enhanced sensitizers. They highlight porphyrin-based and other nanomaterial-augmented strategies and suggest that advanced equipment and smart nanomaterials can help SDT move toward clinical translation.
Studied with: ultrasound, photodynamic therapy.
Key findings
- SDT combines low-intensity ultrasound and sonosensitizers and offers higher tissue-penetrating capability than PDT for deeper lesions.
- Effectiveness and feasibility of SDT depend on both stable/flexible apparatus and screening of sonosensitizers with good specificity and safety.
- Key equipment technologies discussed include ultrasonic dose settings, sonosensitizer screening, tumor positioning, temperature monitoring, and reactive oxygen species (ROS) detection.
- State-of-the-art multifunctional SDT equipment that integrates diagnosis and treatment for more accurate SDT is introduced.
- Overview of sonosensitizer development ranges from small molecular sensitizers to nano/micro-enhanced sensitizers.
- Types of nanomaterial-augmented SDT discussed include porphyrin-based, porphyrin-like, inorganic, and organic-inorganic hybrid nanomaterials with various strategies to improve therapeutic efficacy.
- Authors conclude that advanced equipment, smart nanomaterial-based sonosensitizers, and multidisciplinary collaboration will promote rapid development and clinical translation of SDT.
Limitations: Review article only — presents synthesis and discussion rather than new experimental or clinical data.; Abstract does not report human clinical trial results or quantitative effectiveness/safety outcomes.; Focus is broad and technological; specific comparative efficacy and safety data across sensitizers or devices are not provided in the abstract.; Translational challenges are noted conceptually but the abstract does not provide empirical evidence resolving those challenges..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
OtherFormulationReported positivePreclinical onlyTier 1 · lab
Molecular & cellular oncology · Jan 2021
The paper describes genetically engineered magnetic nanocages called eMIONs, made from encapsulin-produced magnetic iron oxide nanocomposites. The authors state these eMIONs may have improved magnetic-to-thermal conversion efficiency and biocompatibility compared with currently available agents, and suggest they have potential as clinically translatable magnetic hyperthermia therapy agents for cancer.
Key findings
- Current magnetic hyperthermia agents have poor magnetic-to-thermal conversion efficiency and biocompatibility (as stated).
- The authors describe genetically engineered magnetic nanocages (eMIONs) composed of encapsulin-produced magnetic iron oxide nanocomposites.
- The authors propose that eMIONs have great potential as clinically translatable agents for magnetic hyperthermia and for cancer magneto-catalytic theranostics.
Limitations: Abstract contains no experimental methods, results, species, or sample size.; Claims are presented as potential/anticipated benefits rather than demonstrated findings.; No quantitative data or comparative metrics provided in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Animal studyFormulationReported positivePreclinical onlyTier 2 · animal
RSC advances · Mar 2018 · mouse 4T1 breast cancer xenograft study
The authors developed a contractible hydroxypropyl methyl cellulose (HPMC)/Fe3O4 hydrogel designed to release doxorubicin in response to pH and an applied magnetic stimulus. In vitro, the DOX-loaded hydrogel showed notable pH-sensitive drug release. In mice bearing 4T1 breast cancer xenografts, combined chemo-magnetic hyperthermia treatment with the hydrogel led to recovery without recurrence or metastasis and was reported to produce reduced toxicity and superior anticancer effects.
Studied with: doxorubicin, magnetic hyperthermia.
Key findings
- A contractible HPMC/Fe3O4 hydrogel with dual pH- and magnetic-response properties was developed as a drug delivery system.
- The HPMC/Fe3O4/DOX hydrogel displayed a remarkable pH-sensitive drug release profile in vitro.
- After synergistic chemo-magnetic hyperthermia treatment, mice with 4T1 breast cancer xenografts recovered without any recurrence or metastasis.
- The combined pH- and magnetic-hyperthermia response reportedly produced reduced toxicity and superior anticancer effects.
Limitations: Preclinical study limited to in vitro experiments and a single mouse xenograft model (4T1); results may not translate to humans.; Abstract does not report sample size, dosing details, treatment schedule, control groups, or follow-up duration.; Efficacy and safety assessments appear limited to the animal model; no clinical/human data provided..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Lab · in vitroFormulationReported positivePreclinical onlyTier 1 · lab
Journal of biomedical nanotechnology · Jan 2016
breast cancer (MDA-MB-231 cell line)
The authors synthesized hyaluronic acid (HA)-modified magnetic hydroxyapatite nanocrystals and characterized their physicochemical properties. They report successful immobilization of HA via a PEG spacer, good biocompatibility, adequate biodegradation, superparamagnetic behavior, and uptake/localization of the particles into HA-receptor–overexpressing cancer cells (e.g., MDA-MB-231), proposing their use as heat mediators for intracellular hyperthermia in cancer therapy.
Key findings
- HA targeting moiety conjugated by a poly(ethylene glycol) (PEG) spacer arm was successfully immobilized on the surface of mHAP.
- HA-modified mHAP possesses relatively good biocompatibility, an adequate biodegradation rate and superparamagnetic properties.
- HA-modified mHAP could be localized and internalized into HA receptor-overexpressed malignant cells (e.g., MDA-MB-231 cell).
- HA-modified mHAP can be used as the heat generating agent for intracellular hyperthermia, indicating promise as a targeting nanoagent for intracellular hyperthermia cancer therapy.
Limitations: Findings are reported at the in vitro/cell-line level only; no in vivo or clinical data in the abstract.; Abstract does not report quantitative efficacy or safety metrics.; Mechanistic details beyond particle uptake and heat-generation potential are not fully elucidated in the abstract.; No assessment of in vivo biodistribution, toxicity, or therapeutic efficacy is reported..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationInconclusivePreclinical onlyTier 1 · lab
Gels (Basel, Switzerland) · Sep 2015 · tutorial review (narrative)
unspecified tumor tissue / cancer (general)
This tutorial review summarizes the properties and formulations of biocompatible thermo-responsive magnetic gel composites proposed for magnetic hyperthermia cancer therapy. It explains that magnetic particles generate heat under an external alternating magnetic field (via hysteresis loss), that heating can raise tissue temperature into the hyperthermia range, and that thermo-responsive gels can undergo volume changes and potentially release previously entrapped anti-cancer drug molecules.
Reported effect: hyperthermia_temperature_range 41
Studied with: radiation, anti-cancer drugs.
Key findings
- Magnetic hyperthermia involves introducing magnetic micro/nanoparticles into tumor tissue and applying an external magnetic field to heat the area.
- Heating arises mainly from hysteresis loss in magnetic particles subjected to a magnetic field, raising system temperature.
- Thermo-responsive gels, once temperature crosses their lower critical solution temperature (LCST), undergo large volume changes and may deliver anti-cancer drug molecules previously entrapped in their networks.
- The review describes main properties and formulations of magnetic gel composites conceived for magnetic hyperthermia therapy.
Limitations: This is a tutorial/narrative review and does not present original experimental data.; Abstract does not report any in vivo or human clinical data or quantitative efficacy outcomes.; No specific tumor types, sample sizes, or experimental conditions are provided in the abstract.; No information on safety, dosing, or clinical feasibility is provided in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Lab · in vitroFormulationReported positivePreclinical onlyTier 1 · lab
Biomaterials · Jul 2014
The authors engineered a fusion "tetraspecific" ligand that recognizes four cancer-associated receptors (VEGFR2, αvβ3 integrin, EGFR, HER2) and can be highly expressed and purified from E. coli. In vitro binding studies (SPR, BLI) showed each subunit binds its target similarly to monospecific ligands, and when conjugated to gold nanoparticles the ligand enabled target-dependent hyperthermic killing of cancer cell lines; the ligand can bind more than one receptor on the same cell.
Studied with: gold nanoparticles (AuNPs).
Key findings
- A tetraspecific fusion protein ligand recognizing VEGFR2, αvβ3 integrin, EGFR, and HER2 was generated by sequentially connecting four targeting subunits via flexible linkers.
- The fusion protein can be highly expressed in Escherichia coli and purified to near homogeneity.
- SPR, BLI, and cellular binding analyses indicated each targeting subunit in the tetraspecific fusion protein recognized its receptor proximally to the corresponding monospecific ligands.
- The tetraspecific ligand was attached to gold nanoparticles (AuNPs) and enabled efficient target-dependent hyperthermic killing of various cancer cell lines; killing was achieved only when AuNPs were conjugated with the tetraspecific ligand.
- In vitro assays showed the tetraspecific ligand can simultaneously interact with more than one receptor (e.g., EGFR and HER2) on the same cell, consistent with multivalency and synergistic binding.
Limitations: All reported experiments were in vitro (cell lines); no in vivo or clinical data are presented in the abstract.; The abstract does not specify which cancer cell lines or quantitative efficacy measures were used.; Safety, toxicity, pharmacokinetics, and immunogenicity of the ligand-AuNP constructs are not addressed.; No sample sizes, statistical values, or numeric outcome metrics are reported in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewFormulationInconclusivePreclinical onlyTier 1 · lab
International journal of pharmaceutics · Jan 2011 · narrative review
This narrative review summarizes recent research on stimuli-responsive magnetic particles and gels for biomedical applications. It describes temperature- and pH-sensitive "smart" polymers combined with magnetic nanoparticles, their preparation methods, and discusses in vivo uses including MRI contrast, magnetic hyperthermia for cancer, and targeted delivery. The paper surveys the literature on various stimuli-responsive magnetic systems and gels.
Key findings
- Magnetic nanoparticles have been studied as magnetic carriers and exploited as delivery vectors and MRI agents.
- Magnetic particles are proposed as mediators of hyperthermia cancer treatment and for targeted therapies.
- There is substantial interest in "smart" polymers that respond to environmental changes such as temperature and pH.
- The review describes types of stimuli-sensitive systems (mainly temperature- and pH-sensitive polymers), their combination with magnetic properties, and preparation methods.
- The article discusses main in vivo biomedical applications and surveys recent literature on stimuli-responsive magnetic gels.
Limitations: This is a narrative review and does not present new experimental data.; Abstract does not indicate systematic review methods or criteria for study selection.; No specific clinical trial data, species, sample sizes, or quantitative outcomes are reported in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewFormulationMixed resultsPreclinical onlyTier 4 · clinical
Advanced drug delivery reviews · Jun 2009 · review
This is a review of engineered magnetic nanoparticles (MNPs), describing their uses in imaging, guided delivery, hyperthermia and other biomedical applications, and discussing emerging theragnostic applications. The authors summarize evidence that certain nanoparticle properties can increase cytotoxic potential via oxidative stress followed by inflammation and DNA damage, and they discuss how size, composition and surface chemistry affect uptake, biodistribution, macrophage recognition and toxicity.
Studied with: drug delivery, gene delivery, magnetic hyperthermia, MRI-guided therapy, cell tracking.
Key findings
- MNPs have been applied to MRI, guided drug and gene delivery, magnetic hyperthermia cancer therapy, tissue engineering, cell tracking and bioseparation.
- Theragnostic applications are emerging, e.g., MRI-guided cell replacement therapy and MRI-based imaging of cancer-specific gene delivery.
- Certain nanoparticle properties (enhanced reactive area, ability to cross barriers, resistance to biodegradation) can amplify cytotoxic potential relative to molecular or bulk counterparts.
- A 3-tier paradigm of nanotoxicity is described: activation of reactive oxygen species (tier I), a proinflammatory response (tier II), and DNA damage leading to apoptosis and mutagenesis (tier III).
- In vivo administered MNPs are rapidly challenged by macrophages of the reticuloendothelial system (RES), reducing circulation time and potentially limiting efficacy.
- Size, composition and surface chemistry influence intracellular uptake, biodistribution, macrophage recognition and cytotoxicity, and engineering strategies are reviewed to optimize MNPs for biomedical use.
Limitations: This article is a review and presents synthesis of existing studies rather than new primary experimental data.; Findings are based on heterogeneous preclinical and translational studies, so generalizability to human clinical outcomes is uncertain.; The abstract notes caveats in nanotoxicity assessments, implying variability and potential limitations in the underlying evidence base..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text